Rheumatoid Arthritis Therapeutics Market

Rheumatoid arthritis Therapeutics Market is valued at USD 25.363 billion in 2019 and expected to reach USD 35.98 billion by 2026 with a CAGR of 4.92% over the forecast period.

Increasing new therapeutic options for rheumatoid arthritis is driving the rheumatoid arthritis therapeutics market

Rheumatoid Arthritis Therapeutics Leading Vendors

• Gilead Sciences
• Roche
• Johnson & Johnson
• Eli Lilly and Company
• UCB
• Aclaris Therapeutics
• Bristol-Myers Squibb
• Amgen
• Pfizer
• Celgene
• Can-Fite BioPharma Ltd. 

Scope of Global Rheumatoid arthritis therapeutics Market Reports –

Rheumatoid arthritis is an inflammatory disease that affects different body systems along with joints such as skin, eyes, lungs, heart and blood vessels. This disease occurs when patient’s immune system mistakenly attacks its own body’s tissues. It mainly affects the lining of joints, causes a painful swelling which ultimately result in bone erosion, joint deformity etc. which can be treated through improved medications, for instance, To relieve pain and swelling rapidly and to gain control of the inflammation, glucocorticoids (GC) are used extensively in acute disease flares either orally or as intraarticular injections. To control inflammation in the long term, Disease Modifying Anti-Rheumatic Drugs (DMARD) to spare glucocorticoids are used.

Global rheumatoid arthritis therapeutics market report is segmented on the basis of product, distribution channel and by regional & country level. Based on product, global rheumatoid arthritis therapeutics market is classified as biologics, Non-Biologics, Non-Steroidal Anti-Inflammataory Drugs (NSAIDs), Synthetic Disease-Modifying Antirheumatic Drugs (sDMARDs) and other. Based upon distribution channel, global rheumatoid arthritis therapeutics market is classified into hospital pharmacy, retail pharmacy and online pharmacy.

The regions covered in this rheumatoid arthritis therapeutics market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Rheumatoid arthritis therapeutics Market Reports-

Some major key players for global rheumatoid arthritis therapeutics market are Gilead Sciences, Roche, Johnson & Johnson, Eli Lilly and Company, UCB, Aclaris Therapeutics, Bristol-Myers Squibb, Amgen, Pfizer, Celgene, Can-Fite BioPharma Ltd. and others.

Rheumatoid arthritis therapeutics Market Dynamics –

The rising prevalence of rheumatoid arthritis worldwide, introduction of new therapeutic agents and government support on high cost treatment products are some of the major factors driving the rheumatoid arthritis market. These therapeutic treatment stops inflammation, relieve symptoms, prevent joint and organ damages and decreases long term complications which attracts rheumatoid arthritis patients to opt for these treatments, which results in market growth. The prevalence of rheumatoid arthritis is in between 0.3% to 1% according to World Health Organization (WHO) and mainly occurs at the age of 35 and 50 years. Within 10 years of inset of this disease, at least 50% of patients could not do full time job in developed countries which affects their family as well as economy up to some extent. Most patients of this disease need frequent continuous treatment to stop progress of disease which results in increasing business of the corresponding therapeutics.  Conventional disease-modifying antirheumatic drugs ((DMARDs) is the most general therapy for Rheumatoid Arthritis such as sulphasalazine, methotrexate and hydroxychloroquine. These drugs are available in different dosage forms and each dosage form having a different treatment field. Biological DMARD comprises biologic agents that are approved by government agencies for the treatment of rheumatoid arthritis. Next-generation antibody therapeutics is expected to create more opportunity for the market growth in future. However, high cost associated with the therapeutic treatments is expected to restraint the market up to some extent.

Rheumatoid arthritis therapeuticss are usually utilized as actuators and sensors, and their associated ""stimulus"" and ""response"" is depicted in (Table 1). Major advantages of Rheumatoid arthritis therapeutics actuators and sensors include high energy density, fast response, compact size, and fewer moving parts. Rheumatoid arthritis therapeuticss are usually utilized as actuators and sensors, and their associated ""stimulus"" and ""response"" is depicted in (Table 1). Major advantages of Rheumatoid arthritis therapeutics actuators and sensors include high energy density, fast response, compact size, and fewer moving parts. Rheumatoid arthritis therapeuticss are usually utilized as actuators and sensors, and their associated ""stimulus"" and ""response"" is depicted in (Table 1). Major advantages of Rheumatoid arthritis therapeutics actuators and sensors include high energy density, fast response, compact size, and fewer moving parts. Rheumatoid arthritis therapeuticss are usually utilized as actuators and sensors, and their associated ""stimulus"" and ""response"" is depicted in (Table 1). Major advantages of Rheumatoid arthritis therapeutics actuators and sensors include high energy density, fast response, compact size, and fewer moving parts.

Global Rheumatoid arthritis therapeutics Market Regional Analysis –

North America is dominating the rheumatoid arthritis (RA) therapeutics market with highest share due to increasing prevalence of rheumatoid arthritis, growing awareness on treatment of this disease and increasing healthcare spending. For example, 41 people are diagnosed with RA out of100,000 every year in USA and the lifetime risk of developing RA is 3.6 % for women and 1.7 percent for men in this region. The estimated national medical costs of arthritis in 2013 was USD 140 billion from which medical costs was USD 140 billion whereas, which shows the prevalence of RA treatment. Europe is the second dominating market of RA due to prevalence of the disease, adoption rate of treatment, and research & development activities on this disease. Government initiatives as well as recommendations provided by international organizations helps the market to expand in this, for example, the European League Against Rheumatism (EULAR) has composed 10 international recommendations on how to treat patients. On the other hand, growing penetration of rheumatoid arthritis treatment drugs, especially biologics and increasing development of healthcare infrastructure is expected to expand the market of RA in Asia-Pacific region.

Key Benefits for Global Rheumatoid arthritis therapeutics Market Reports–

Global Rheumatoid arthritis therapeutics Market report covers in depth historical and forecast analysis.

Global Rheumatoid arthritis therapeutics Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Rheumatoid arthritis therapeutics Market report helps to identify opportunities in marketplace.

Global Rheumatoid arthritis therapeutics Market report covers extensive analysis of emerging trends and competitive landscape.

Global Rheumatoid Arthritis Therapeutics Market Segmentation –

by Product -(Biologics, Non-Biologics, Non-Steroidal Anti-Inflammataory Drugs (NSAIDs), Synthetic Disease-Modifying Antirheumatic Drugs (sDMARDs), Other)

by Distribution Channel- (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

By Regional & Country Analysis
North America, US, Mexico, Chily, UK, France, Germany, Italy, Asia Pacific, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa